Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.
An ABC News-syndicated piece featuring emergency physician and medical toxicologist Dr. Stephanie Widmer ran across ABC affiliates including ABC7 San Francisco, ABC11 Raleigh-Durham, ABC7 Los Angeles, ABC7 Chicago, and ABC13 Houston this week. The piece flagged falsified peptide products tested at arsenic levels up to 10× the toxicity limit for injectables, lead contamination, purity ranging from 5–75%, and documented mislabeling. Cited safety concerns include cardiovascular strain, insulin resistance, psychiatric instability, and blood clots. The breadth of the broadcast parallels FOX's syndicated explainer earlier in the week.
On April 24 the FDA awarded three National Priority Review Vouchers to companies developing psychedelic therapies: Compass Pathways (psilocybin for treatment-resistant depression), Otsuka Pharmaceutical, and the non-profit Usona Institute (methylone for PTSD). This is the same voucher program that enabled Lilly's Foundayo (orforglipron) to be reviewed in 50 days. The program's expansion into psychedelics signals FDA's continued willingness to use priority vouchers aggressively for novel mental health and metabolic candidates — with peptide developers watching closely ahead of the July PCAC meeting.
The FDA granted accelerated approval April 23 for Regeneron's Otarmeni (lunsotogene parvec-cwha), a gene therapy for certain forms of genetic hearing loss. Otarmeni is the first gene therapy cleared under the FDA's National Priority Voucher program and will be offered to eligible patients at no cost. The approval validates the priority voucher pathway's applicability beyond GLP-1 drugs and establishes regulatory precedent that peptide developers may invoke if the July PCAC meeting produces favorable reclassification recommendations.
After CVS/Aetna, UnitedHealth, and other insurers declined to participate in the BALANCE five-year pilot, CMS announced the Medicare GLP-1 Bridge program — originally scheduled to end December 31, 2026 — will now be extended through 2027 with the federal government directly paying for seniors' obesity drug coverage. The pivot acknowledges that the insurer-funded pilot structure was untenable; CMS said the extension will allow longer data collection on which patients benefit most before any transition back to private payers.
Yahoo published an April 23 consumer-facing explainer titled "Wait, So Are Peptides Legal Now?" — the most widely-circulated translation of last week's FDA Category 2 removal for a mainstream audience. The piece walks through which 12 peptides were removed from the restricted list, what the July 23-24 PCAC meeting will actually decide, the distinction between reclassification and FDA approval, and the practical implications for compounding pharmacies and patients. The article marks the peptide-regulation story's transition into general consumer awareness.
Hyman, Phelps & McNamara's FDA Law Blog published a comprehensive two-part analysis April 22 walking compounders and peptide industry stakeholders through the Federal Register notice, the July 23-24 PCAC meeting structure, the distinction between Category 2 removal and Section 503A Bulk Drug Substances List inclusion, and the notice-and-comment rulemaking that must follow any PCAC recommendation. The analysis emphasizes that the July 9, 2026 written comment deadline and June 30 oral presentation notification are critical inflection points for industry engagement.
The Trump administration on April 22 cancelled the five-year BALANCE Medicare model that would have had private insurers pay for Wegovy and Zepbound as a regular benefit, after CVS opted out citing a projected $1.4 billion cost over 10 years. Medicare will instead cover the drugs directly through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, with beneficiaries paying $50/month copays.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
An April 22 NPR report citing GoodRx research found that 12 million people each lost insurance coverage for Wegovy and Zepbound between 2025 and 2026, while 88% of those still covered face restrictions like prior authorization or BMI 40+ requirements. About 60% of GLP-1 users now pay out of pocket — often hundreds of dollars monthly — reframing the affordability debate after the BALANCE model's cancellation.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.
Scientific American published a comprehensive April 18 feature examining the self-injection wellness peptide movement, focusing on BPC-157, TB-500, GHK-Cu, KPV, and ipamorelin. The piece notes that only three small pilot studies have looked at BPC-157 in humans, that most evidence is from rodent models, and that consumers are ordering the compounds from overseas — usually from China — while the FDA prepares to review the category at its July advisory panel.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.
The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.